203 related articles for article (PubMed ID: 30766682)
1. Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture.
Saraya T; Tamura M; Kasuga K; Fujiwara M; Takizawa H
Respirol Case Rep; 2019 Apr; 7(3):e00403. PubMed ID: 30766682
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore.
Chua CG; Low JZ; Lim WY; Manghani M
Ann Acad Med Singap; 2022 Dec; 51(12):755-765. PubMed ID: 36592144
[TBL] [Abstract][Full Text] [Related]
4. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
[TBL] [Abstract][Full Text] [Related]
5. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
8. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract][Full Text] [Related]
9. Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.
Sato Y; Tanino Y; Nikaido T; Togawa R; Kawamata T; Watanabe N; Sato R; Yamada R; Onuma T; Tomita H; Saito M; Rikimaru M; Morimoto J; Suzuki Y; Minemura H; Saito J; Kanazawa K; Yamada S; Hashimoto Y; Shibata Y
BMC Pulm Med; 2022 May; 22(1):191. PubMed ID: 35549684
[TBL] [Abstract][Full Text] [Related]
10. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
12. Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-γ antibody.
Zhao Q; Chen Y; Diao L; Zhang S; Wu D; Xue F; Xia Q; Li H; Zheng J; Cao H
Rheumatology (Oxford); 2022 May; 61(5):2176-2184. PubMed ID: 34508564
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence.
Ferronato M; Lalanne C; Quarneti C; Cevolani M; Ricci C; Granito A; Muratori L; Lenzi M
J Clin Transl Hepatol; 2023 Feb; 11(1):253-259. PubMed ID: 36406323
[TBL] [Abstract][Full Text] [Related]
14. Case report of anti-transcription intermediary factor-1-γ/α antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor.
Ito K; Imafuku S; Hamaguchi Y; Fujimoto M; Nakayama J
J Dermatol; 2013 Jul; 40(7):567-9. PubMed ID: 23663102
[TBL] [Abstract][Full Text] [Related]
15. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report.
Kishi T; Tani Y; Okiyama N; Mizuochi K; Ichimura Y; Harigai M; Nagata S; Miyamae T
Pediatr Rheumatol Online J; 2021 Mar; 19(1):34. PubMed ID: 33740993
[TBL] [Abstract][Full Text] [Related]
16. A Case Report of Anti-TIF1-
Hounoki H; Onose T; Yamazaki M; Asano R; Yamaguchi S; Shinoda K; Tobe K; Noguchi A; Hirabayashi K
Case Rep Rheumatol; 2023; 2023():8837463. PubMed ID: 38116495
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome].
Xing XY; Zhang JX; Zhu FY; Wang YF; Zhou XY; Li YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1214-1218. PubMed ID: 36533358
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
